TP53 and acute myeloid leukemia: TP53 mutant AML with biallelic or multi-hit alterations may bypass cholesterol and mevalonate-dependent vulnerabilities, and metabolic plasticity and compensatory pathways (e.g., increased fatty acid oxidation or acetate utilization) may blunt the true effects of statins.